1 / 16

Introduction of a Men A conjugate vaccine: How will this change meningitis in Africa?

Introduction of a Men A conjugate vaccine: How will this change meningitis in Africa? GEO Meningitis Environmental Risk Consultative Meeting Geneva, 26-27 September, 2007. F Marc LaForce, MD. Outline of Presentation. How does Neisseria meningitidis spread in a population?

tana-gilliam
Télécharger la présentation

Introduction of a Men A conjugate vaccine: How will this change meningitis in Africa?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Introduction of a Men A conjugate vaccine: How will this change meningitis in Africa? GEO Meningitis Environmental Risk Consultative Meeting Geneva, 26-27 September, 2007 F Marc LaForce, MD

  2. Outline of Presentation • How does Neisseria meningitidis spread in a population? • Can this spread be blocked by immunization? • Likely public health impact after the introduction of a Men A conjugate vaccine • What will not happen

  3. Flow of Neisseria meningitidis Through a Population Reservoir Courtesy Drs. Maiden and McLennan Courtesy Dr. Martin Maiden

  4. Why are conjugate vaccines different? • In addition to providing individual protection against serious disease, they also reduce asymptomatic carriage • Reduced carriage  lower transmission  indirect protection • even unvaccinated individuals in the population are at reduced risk of disease

  5. Population Effects of Men C Conjugate Vaccines: The Development of Herd Immunity reservoir Courtesy Dr.Martin Maiden

  6. Flow of colonization in a population where all are susceptible Number of infectious cycles 1 2 3 4 5 81 27 Number colonized per infectious cycle 1 3 9 27 81

  7. Flow of colonization in a population where two thirds of the population are protected Number of infectious cycles 1 2 3 4 5 Number colonized in each infectious cycle 1 1 1 1 1

  8. Impact of PNC-7 vaccination in USA Source: MMWR weekly, 2005 / 54(36);893-897

  9. MenC vaccination in England & Wales Trotter et al, Am J Epi 2005, 162: 89-100

  10. Introduction of Men A conjugate vaccine in Africa All 1-29 year olds in Burkina Faso to receive one dose of Men A conjugate vaccine 2008 Campaigns in Mali and Niger 2009 Begin campaigns in Nigeria, Sudan and Ethiopia 2010 Add more belt countries 2011-2020

  11. Potential Public Health Benefit From a Men A Conjugate Vaccine in Nigeria Over 130,000 potentially preventable cases of meningitis in years 77,78,86,87 and 96 65 70 75 80 85 90 95 00

  12. Potential Public Health Benefit from the Prevention of Men A Epidemics in Mali Epidemic meningitis in Mali 1965-2003 Cases Over 32,000 potentially preventable cases during epidemic years 69,70,81,82,96,97 and 98 65 70 75 80 85 90 95 00 Years

  13. Epidemic disease Endemic disease Residual endemic disease 81 85 90 95 00 Potential Impact of a Men A Conjugate Vaccine 81 85 90 95 00

  14. What will not happen • Acute meningitis cases will not be eliminated (particularly important in the group less than two years of age where most cases of acute bacterial meningitis are due to Hemophilus and pneumococci)

  15. The Meningitis Vaccine Project

More Related